1

Size: px

Start display at page:

Download "1"

缇肪僪
9 years ago
Views:

2 1

5 4

6 5

7 % 34 19% 33 19% % 23 13% % % 22 12% ,828 29% 51,136 15% 87,485 25% 63,509 18% 37,813 11% 6,363 2% ,134 6

8 % % 93 9% 77 7% 1, ,386 3% 92,513 4% 178,668 8% 431,073 19% 946,943 41% 324,192 14% 20,633 1% 221,333 10% 93 2,293,741 7

9 % 9 25% 10 28% 8 22% ,866 21% 25,700 38% 15,535 23% 12,343 18% 93 67,444 8

10 % 5 15% 20 61% ,203 28% 8,733 14% 34,588 58% 93 60,524 9

12 WIN Aw a r d WIN Global 10 WIN Japan WIN Award 1996 WIN Global WIN Ta i w a n 14 WIN Aw a r d WIN Global WIN Global WIN Award 11

13 S u r r y 12

14 L M

15 L M A N - L M

16 ICRP 2005 IRPA-11 Lessons learned from IRPA 11 Radiation Protection Standards: Now and the Future Radiation Safety for the Design and Operation of Particle Accelerators Brookhaven Technical Basis Document for Internal Dosimetry and Urine Bioassay Programs Perspectives of Managing Radiation Protection in United States The Dose Reduction Strategy and ALARA Trend of Nuclear Power Plants in Taiwan ALARA Radiation Dose Reduction Measures on Management Perspectives 15

24 , % 5. 4 % 4. 8 % 7. 2 % 23

26 ,

27 S c h i z o p h r e n i a Alzheimer's disease Parkinson's disease Positron Emission To m o g r a p h y, P E T S i n g l e - Photon Emission Computed To m o g r a p h y, SPECT 93 FDDNP amyloid beta plaques F D D N P 2 -( 1, 1 - d i c y a n o p r o p e n y l )- 6 -[( 2 - fluoroethyl) methylamino] naphthalene 92 F D D N P TsDDNP 200 mg 95 % C8 Sep-Pa k column F D D N P H P L C 26

28 T L C F D D N P m C i 20 ~ 30 % T L C 85 % F D D N P F D D N P PET -123-ADAM s e r o t o n i n synaptic cleft S P E C T P E T A D A M ( 2 -[[ 2 -[( d i m e t h y l a m i n o ) m e t h y l ] p h e n y l ] t h i o ]- 5 - i o d o p h e n y p a m i n e ) S n A D A M [ 2 -(( 2 - a m i n o t r i - n - butyltinphenyl) thio)benzyl] dimethylamine S n A D A M 300 mg 95 % S n A D A M 5 % p H C 8 I ADAM 50 mci 40% HPLC 90 % 48-99m-TRODAT-1 Parkinson's Disease d o p a m i n e - 99 m - T R O D AT- 1 (2beta-((N,N'-bis(2-mercaptoethyl) ethylene 27

29 diamino)methyl), 3beta-(4-chlorophenyl)tropane) - 99 m - T R O D AT m m - T R O D AT % > 90 % < 35 E U / m l MIPP ( R )- N - m e t h y l - 3 -( 2 - iodophenoxy)- 3-phenylpropanamine M I P P n i s o x e t i n e ( R )-[ I ] M I P P ( S )-(-)- 3 - c h l o r o p h e n l y p r o p a n o l t r i p h e n y l p h o s p h i n e diethyl azodicarboxylate 2 - b r o m o p h e n o l M i t s u n o b u ( R )- M B P P ( R ) - [ I ] M I P P ( R ) - M B P P M S P P ( R )- N - methyl-3-(2-tributylstannylphenoxy)- 3-phenylpropanamine MSPP M I P P M S P P ( R ) - M I P P M I P P M B P P M S P P MIPP 28

30 -123-IBZM D2 r e c e p t o r To u r e t t e ' s s y n d r o m e D2 D2 r e c e p t o r D2 receptor occupancy I B Z M ( ( S )-(-) h y d r o x y i o d o m e t h o x y - N -[( 1 - e t h y l p y r r o l i d i n y ) m e t h y l ] benzamide) IBZM ph 4 e l e c t r o p h i l i c B Z M Accubound C % T L C I B Z M 95 % I B Z M 0. 2 m M i l l i p o r e - 99 m - T R O D AT I B Z M PARKINSON S DISEASE MSA ESSENTIALTREMOR TRODAT-1 IBZM -99m-TRODAT IBZM 29

31 F D G m i c r o P E T - 99 m - H M PAO m i c r o S P E C T F D G %ID/g 0.50 A B 0-18-FDG micropet A. -18-FDG B. -18-FDG 30

32 m i c r o P E T m i c r o S P E C T / C T m i c r o P E T m i c r o S P E C T PET S P E C T Probabilistic Risk Assessment, PRA Nucleonics We e k Inside NRC I A E A 2004 Risk Monitors

33 T I R M - 2 I A E A T I R M - 2 P R A P R A What can go wrong? How likely is it? What are the consequences? P R A 74 P R A P R A P R 76 P R A A P R A P R A P R A P R A TIRM-2 CDF LERF I N E R F T

34 F TA 1970 P R A 7 5 INERFT F TA P R A F TA P R A 85 P R A P R A P R A P R A 91 5 I N E R F T 92 3 P R A P R A

35 9 1 4 P R A P R A P R A P R A / Q R A P R A M I T G e o r g e A p o s t o l a k i s P R A 120 N A S A P R A P R A 34

36 921 10CFR50 Appendix R P R A P R A A P R A P R A 94 P R A 35

37 PRA Plasma Thermal plasma Cold plasma 10, 000 1, 400 ~ 1, , ,

38 kw INER-20RF ~1994 INER-100NT ~1996 INER-1200T 1, ~1998 INER-10NT ~2001 INER-1000NT 1, INER-3000NT 3, ~2005 INER-3000T 3, ~2006 INER-PF kw ~1996 INER-PF250 INER-PF250R kw ~ kw ~2005 INER-PF kw ~ kw 1 INER-PF1000 INER-PF kw 1 1,000 TBD 3,000 kw 1 3,000 TBD 20 D C / R F ~3,000 kg/cm 2 8 ~ 15 >15 kg/cm 2 > , 200 I N E R T I N E R - P F

39 I N E R - P F R , 000 ~ 2, ~ 1, / 5 ~ 1 /

40 ,

41 95% Binder PVA 5% % Binder % 50% 1200 G D P G N 6 % 6. 3 % 87 % % % % % 40

42 SOFC YSZ Da~150 nm SOFC d=10~30nm SOFC S O F C D M F S O F C 150 nm YSZ/NiO 50/50 10 ~ 30 n m 41

43 MWCNT TEM 670 Balance of Plant BOP 1 atm G C TO O L A i r / F u e l = fully external reforming 77.8 % 86.6% Steam reforming 7 65 ~ % ~ % 100 % 97.6%~100% SOFC 300 % 1 95 % 1400 psi 3.3 wt% D M F C N a f i o n N a f i o n P t / C N T P t - Ru/ CNT P t - Ru-Ir/ CNT D M F C 1. 5 P t ~ 2 n m M E A DMFC Stack DMFC 3 C I I I - V I I I - V 42

44 I I I - V 25 % % 10 ~ 14 % 150 W % INER DMFC InGaP/GaAs/Ge I-V 43

45 3% % % 4. 7 % % % 4 % 1 ~ 2 40 % 80 % 3 ~ 5 6 ~ 10 M W kw S O F C 5 kw k W S O F C 60% L E D A P C V D M O C V D L E E - g u n E v a p o r a t o r L E D 7-15 lm/w 20 lm/w 44

46 ~

48 I A E A I C R P I A E A I C R P I A E A TECDOC T E C D O C D S e x c l u s i o n e x e m p t i o n c l e a r a n c e

49 8 R S - G I A E A I A E A R S - G T E C D O C , S u r r y 20 48

50 Surry Susqhehanna 49

51 1944 Oak Ridge 50 SFR

52 L'Aube Barnwell 51

53 1906 4, R a T h A C P b B i T L R a P b B i P b

54 - 232 T h T L U B i U B i U Th R a T1 / 2= R a T1 / 2= U R a T1 / 2= Ra

56 C E A O E C D / N E A J N E S 2004 P B N C O E C D / N E A I A E A I C R P

57 Additional Pr o t o c o l

58 95 %

59 % % 78 %

61 NA /84 8/101 8/123 4/143 14/393 NA NA NA 9/41 9/

63 NRC IN Potential Vulnerability of Plant Computer Network to Worm Infection GCB 4. EOC A B KV DCR NRC 10CFR50.48 c NFPA- 805 RG RG 1.26 Rev. 3 2/76 note b ASME Code N-symbol need not be applied 2. RPV SETTING PSAR Additional Requirements 62

66 ,

70 9 3 69

72 , , , %

73 ~

74 G I S G P S

75 S 74

76 ,

77 19 2, , 756 8,

78 Reactor Oversight Pr o g r a m Significance Determination Process, SDP S D P P R i S E P R i S E I N E R I S K E N I N E R F T E I N E R F T I N E R F T PRiSE 77

79 F S A R F S A R 2 M W 15 m 0. 6 m 0. 1 m 3. 2 m 78 P D A

80 G P S G P R S G I S W N 23 P S A R NRC RG 1.26 RT P S A R 79

81 T R 30 / ~ 21 M e V 10 A h r M C A k e V k e V k e V p, 3 n Te p, 2 n % % N Na124I 1 ma R F 5 ma 10 80

82 m A Einzel lens Einzel lens R F 9 % % 1 MeV 1 ma R F 30 MeV 1 ma [ 18 F]-FLT [ 18 F]- F D G [ 18 F]-FLT [ 18 F]-F18 L-Thymidine Tracer Lab FX-FN [ 18 F]- F LT [ 18 F]- F LT Tubingen PET Center Dr. Machulla [ 18 F]F LT Tracer Lab FX-FN [ 18 F]F LT 20 % [ 18 F]F LT F - 18 > 1Ci [ F]F LT Tracer Lab FX-FN [ 18 F]FLT [ 18 F]- F D G [ 18 F] -99m Ciprofloxacin -99m ciprofloxacin -99m ciprofloxacin 15-99m ciprofloxacin c o u n t e r -99m ciprofloxacin -99m ciprofloxacin

83 -99m ciprofloxacin -99m ciprofloxacin -99m ciprofloxacin -99m ciprofloxacin 67 Ga-DOTA-Tyr3-Octreotide solid-phase peptide synthesis D O TA - Ty r 3 - O c t r e o t i d e 8 ~ 10 D O TA - D - Ph e - C y s - Ty r - D - Tr p - Ly s - T h r - C y s - T h r ( o l ) D O TA - Ty r 3 - O c t r e o t i d e 12 M S D O TA - Ty r 3 - O c t r e o t i d e 5 I - Ty r 1 - S o m a t o s t a t i n ( Ki= 3.95±0.75nM) D O TA - Ty r 3 - O c t r e o t i d e 6 A R 42 J L e w i s 7 G a - D O TA - Ty r 3 - O c t r e o t i d e Micro SPECT D O TA - Tyr3-Octreotide 67 Ga-DOTA-Tyr 3 -Octreotide 3.3mCi/0.3ug AR42J Lewis 4h 8h 24h 48h Micro SPECT N y l o n P E T N y l o n P E T S E M T E M 82

84 Staphylococcus aureus N y l o n P E T P E T VCSEL RCLED Vertical Cavity Surface Emitting L a s e r s : V C S E L s H o n e y w e l l L E D R C L E D V C S E L Spontaneous Emission L a s i n g k e V k e V < 3 A V C S E L R C L E D R C -TRIM code V C S E L R C L E D 500keV 83

85 2 6 / t p d 6 B W R H E S T 84

86 2 / /3 50~1000 nm L a N i5 C H4 670 H RT E M S E M R a m a n S c a t t e r i n g 15~130 nm S i e v e r t 1400 psi 3.3 wt% 85

88 93 93 E O C - 20 E O C - 16 E O C %

89 I A E A ,257 1,032 2, ,743 1,851 1, ,986 3,580 1, ,668 25,424 2,441 97,672 9,070 10, ,724 42,582 8,327 97, ,711 88

93 MTU* 66 3,083 2, ,083 2, ,975 3, ,237 3, , , MTU Metric Tonnes Uranium C F R 7 2 N U R E G N U R E G

94 93 N R C ~ R E S R A D D&D MARSSIM T R R W

96 2,

97 h t t p :// w w w. t r m c. a e c. g o v. t w 93 7,

99 P ~ ng-teq/nm ng-teq/nm ~ ~ P B N C ~

100 ~ J A I F NUPEC NUMO JNES T R R 7 TRR T R R 05.10~ ~17 International Committee for Radionuclide Metrology ICRM Dr. Mike Woods A P M P C G P M ~21 A Kaluba Chitumbo G M P / c G M P G M P / c G M P

101 ~ ~22 ESF Response Time

102 ~06 10~ ~ ~ ~ ~ ~ ~

103 ~ ~ CFR Appendix J Option B RHR ~ ~12.01 EOC~ ~ CPD 102

104 ~ ~ , ~03 A Kaluba Chitumbo ~ C A M P ~ C O O P R A 103

105 x29.5 ISBN NT$ B B GPN ISBN

106 80 (02) (02) ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN No.80, Sec.1, Cheng Kung Rd., Yung-Ho City, Taipei County, Taiwan R.O.C. Tel : (02) Fax : (02) http : // 80 (02) (02) FUEL CYCLE AND MATERIALS ADMINISTRATION ATOMIC ENERGY COUNCIL No.80, Sec.1, Cheng Kung Rd., Yung-Ho City, Taipei County., Taiwan R.O.C. Tel : (02) Fax : (02) http : //fcma.aec.gov.tw 1000 (02) (03) INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL No.1000, Wunhua Rd.,Jiaan Village, Lung-Tan, Tao-Yuan Taiwan R.O.C. Tel : (02) Fax : (03) http : // 823 (07) (07) RADIATION MORNITORING CENTER ATOMIC ENERGY COUNCIL No.823, Cherng-Ching Rd.,Kaohsiung, Taiwan R.O.C. Tel : (07) Fax : (07) http : // ISBN

Bimonthly-57

Bimonthly-57 輻射防護簡訊 78 中華民國 95 年 4 月 1 日出版單位 : 財團法人中華民國輻射防護協會地址 : 新竹市光復路二段 295 號 15 樓之 1 電話 :(03)5722224 電傳 :(03)5722521 編輯委員 : 王昭平尹學禮何偉李四海施建樑翁寶山張寶樹董傳中